A Study of PRN1008 in Adult Patients With Immune Thrombocytopenic Purpura (ITP)

Study Overview

This is an adaptive, open-label, dose-finding study of PRN1008 in patients with ITP who are refractory or relapsed with no available and approved therapeutic options, with a platelet count <30,000/microliter on two counts no sooner than 7 days apart in the 15 days before treatment begins.

Study Description

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

  • ClinicalTrials.gov Identifier: NCT03395210
  • Protocol Number: 18-048
  • Principal Investigator: Jeffrey Zwicker

Recruitment Status

Open

Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

If you need assistance finding a study or if you have any questions, call us at 617-667-7000